Scott Lish Sells 22,727 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 22,727 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $11.07, for a total transaction of $251,587.89. Following the sale, the chief operating officer now directly owns 748,918 shares of the company's stock, valued at approximately $8,290,522.26. This trade represents a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Lish also recently made the following trade(s):

• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The stock was sold at an average price of $13.00, for a total transaction of $719,875.00.
• On Monday, May 5th, Scott Lish sold 12,000 shares of Alphatec stock. The stock was sold at an average price of $12.12, for a total value of $145,440.00.

Alphatec Price Performance

ATEC stock traded down $0.17 during midday trading on Tuesday, reaching $10.85. 1,289,665 shares of the company were exchanged, compared to its average volume of 2,058,999. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $13.14. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -9.43 and a beta of 1.10. The business has a 50-day moving average price of $11.73 and a two-hundred day moving average price of $10.83.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The company had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The firm's revenue for the quarter was up 22.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.34) EPS. As a group, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ATEC. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Wall Street Zen upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price target on shares of Alphatec in a research report on Friday, May 2nd. Piper Sandler reiterated an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $17.89.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Alphatec by 38,433.3% in the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after purchasing an additional 2,306 shares during the last quarter. Comerica Bank raised its position in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Larson Financial Group LLC bought a new position in Alphatec in the first quarter valued at about $54,000. Quarry LP grew its holdings in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new stake in shares of Alphatec during the fourth quarter worth about $76,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.